2025
Endovascular Embolization versus Observation of Congenital Renal Arteriovenous Malformations: A Retrospective Study
Hufnagle J, Fish A, Schlachter T. Endovascular Embolization versus Observation of Congenital Renal Arteriovenous Malformations: A Retrospective Study. Journal Of Vascular And Interventional Radiology 2025, 36: 988-993.e1. PMID: 39938714, DOI: 10.1016/j.jvir.2025.02.001.Peer-Reviewed Original ResearchCongenital renal arteriovenous malformationRenal arteriovenous malformationType I AVMArteriovenous malformationsEndovascular embolizationAdverse eventsImaging review of patientsReview of patientsArteriovenous malformation ruptureFollow-up dataYakes classificationTransarterial embolizationEmbolization groupPresenting symptomsPatient demographicsRetrospective studyProcedural imagingImaging reviewEmbolizationPatientsObservation groupMalformationsComplicationsVessel sizeNephrectomyNephrectomy in autosomal dominant polycystic kidney disease: a consensus statement of the ERA Genes & Kidney Working Group
Geertsema P, Gansevoort R, Arici M, Capasso G, Gall E, Furlano M, Fuster D, Galletti F, Dos Santos V, Gomez M, Goumenos D, Halbritter J, Jambon E, Korst U, Leliveld-Kors A, Musquera M, Figueiredo A, Nijenhuis T, Olsburgh J, Pol R, Sayer J, Stippel D, Torra R, Müller R, Casteleijn N, Alam A, Bammens B, Bartram M, Birn H, Budde K, Cakiroglu F, Castro-Alonso C, Chebib F, Dahl N, de Almeida E, Demoulin N, Devuyst O, Eleftheriadis T, Prlic M, Horie S, Idrizi A, Iyasere O, Janssens P, Jouret F, Luque Y, Mallett A, Mousseaux C, Mrug M, Perrone R, Reiterova J, Robles N, Rroji M, Rudnicki M, Schmitt R, Scolari F, Tesar V, Topaloglu R, Trillini M, Weekers L, Zakrocka I, Spahia N, Kawano H, Muto S. Nephrectomy in autosomal dominant polycystic kidney disease: a consensus statement of the ERA Genes & Kidney Working Group. Nephrology Dialysis Transplantation 2025, 40: 1032-1054. PMID: 39848914, DOI: 10.1093/ndt/gfaf019.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseKidney diseaseWork-upConsensus statementIntermediate risk proceduresAlternative to nephrectomyKidney graft functionDelphi survey roundsEvidence-based algorithmComplication rateAcceptable mortalityKidney embolizationGraft functionRenal embolizationNephrectomyKidney transplantationSurgical techniqueMultidisciplinary consultationSymptom burdenRisk proceduresSurvey roundsTransplant surgeonsEuropean Association
2024
Association between thymectomy and incidence of renal cell carcinoma (RCC).
Barragan-Carrillo R, Ebrahimi H, Chawla N, Salgia N, Castro D, Chehrazi-Raffle A, Dizman N, Hsu J, Meza L, Zengin Z, LeVee A, Tripathi A, Dorff T, Bergerot C, Bergerot P, Eilber K, Dallas K, Pal S. Association between thymectomy and incidence of renal cell carcinoma (RCC). Journal Of Clinical Oncology 2024, 42: 371-371. DOI: 10.1200/jco.2024.42.4_suppl.371.Peer-Reviewed Original ResearchRenal cell carcinomaIncidence of nephrectomyIncidence of renal cell carcinomaMedian age of patientsFrequency of nephrectomyAge of patientsT cell productionProportion of patientsRate of nephrectomyFisher's exact testGeneral populationAge-matched populationICD-9/10 codesPopulation-based cohortPopulation-based studyImmunogenic cancerPrior thymectomyChi-square testCell carcinomaMedian ageSurgical interventionNephrectomyThymectomyExact testOSHPD database
2023
Relationships among Non-Neoplastic Histopathological Features, Kidney Function, Proteinuria, and Other Clinical Factors in Patients Undergoing Nephrectomy
Becerra L, Betancourt J, Elfassy T, Iakymenko O, Thomas D, Isaac F, Fornoni A, Zuo Y, Barisoni L, Contreras G, Mendoza J. Relationships among Non-Neoplastic Histopathological Features, Kidney Function, Proteinuria, and Other Clinical Factors in Patients Undergoing Nephrectomy. Glomerular Diseases 2023, 3: 220-229. PMID: 37915860, PMCID: PMC10616670, DOI: 10.1159/000534339.Peer-Reviewed Original ResearchLower eGFRGlobal glomerulosclerosisInterstitial fibrosisCardiovascular diseaseClinical factorsHistopathological featuresSpecific histopathological featuresGlomerular filtration rateCross-sectional analysisDipstick proteinuriaKidney functionMultivariable analysisFiltration rateKidney parenchymaOutcome measuresProteinuriaRoutine examinationHypertensionPatientsArteriosclerosisEGFRNephrectomyObesityAssociationRegression modelsA0326 Characterization of patients with metastatic renal cell carcinoma treated with or without cytoreductive nephrectomy in the era of combination immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Takemura K, Ernst M, Navani V, Wells J, Bakouny Z, Donskov F, Basappa N, Wood L, Meza L, Pal S, Szabados B, Powles T, Beuselinck B, Mckay R, Lee J, Ernst D, Kapoor A, Yuasa T, Choueiri T, Heng D. A0326 Characterization of patients with metastatic renal cell carcinoma treated with or without cytoreductive nephrectomy in the era of combination immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). European Urology 2023, 83: s473-s474. DOI: 10.1016/s0302-2838(23)00375-5.Peer-Reviewed Original Research
2022
The Impact of Venous Thromboembolism on Mortality and Morbidity During Nephrectomy for Renal Mass
Patel HV, Sterling JA, Srivastava A, Ghodoussipour SB, Jang TL, Grandhi MS, August DA, Rahimi SA, Chung BI, Chang SL, Singer EA. The Impact of Venous Thromboembolism on Mortality and Morbidity During Nephrectomy for Renal Mass. Urology 2022, 168: 122-128. PMID: 35691439, DOI: 10.1016/j.urology.2022.05.033.Peer-Reviewed Original ResearchConceptsPreoperative venous thromboembolismTime of nephrectomyVenous thromboembolismRenal massesMajor complicationsRadical nephrectomyAssociation of VTEPresence of VTEConcurrent venous thromboembolismPremier Healthcare DatabaseDirect hospital costsMultivariable logistic regressionTypes of complicationsHigh rateICU admissionComplication rateSurgical resectionSurgical approachHospital costsNephrectomyPatientsHealthcare databasesComplicationsHigher overall costsLogistic regression
2021
Living Donor Nephrectomy: Approaches, Innovations, and Outcomes
Merola J, Cooper M, Kulkarni S. Living Donor Nephrectomy: Approaches, Innovations, and Outcomes. 2021, 291-302. DOI: 10.1007/978-3-030-53618-3_13.Peer-Reviewed Original ResearchDonor nephrectomySuperior long-term outcomesLong-term outcomesCareful preoperative planningSingle-port surgeryKidney transplantationSurgical riskDeceased donorsOrgan recipientsSurgical approachSurgical considerationsSurgical techniqueKidney donationNephrectomyPreoperative planningInformed consentOutcomesAdequate trainingRiskDonorsAllograftsDonationSurgeryTransplantationSurgeons
2020
Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered.
Meza L, Chehrazi-Raffle A, Pal S. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered. Current Opinion In Urology 2020, 30: 740-742. PMID: 32732626, DOI: 10.1097/mou.0000000000000809.Peer-Reviewed Original Research836 Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score
Maresma M, Marchioni M, Campi R, Minervini A, Kriegmair M, Heck M, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Derweesh I, Ghali F, Autorino R, Veccia A, Roussel E, Albertsen M, Pavan N, Antonellia A, Palumbo C, Capitanio U, Klatte T, Erdem S, Rubio-Briones J, Group Y. 836 Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score. European Urology Open Science 2020, 19: e1266-e1267. DOI: 10.1016/s2666-1683(20)33434-0.Peer-Reviewed Original Research840 Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry
Campi R, Marchioni M, Roussel E, Capitanio U, Klatte T, Kriegmair M, Erdem S, Rubio-Briones J, Minervini A, Heck M, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Derweesh I, Autorino R, Pavan N, Antonelli A, Palumbo C, Guruli G, Ghali F, Amiel T, Mir M, Group Y. 840 Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry. European Urology Open Science 2020, 19: e1274-e1275. DOI: 10.1016/s2666-1683(20)33438-8.Peer-Reviewed Original ResearchRedefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma
Hsiang WR, Kenney PA, Leapman MS. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Current Oncology Reports 2020, 22: 35. PMID: 32170461, DOI: 10.1007/s11912-020-0895-y.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaSystemic therapyRenal cell carcinomaCytoreductive nephrectomySurgical therapyCell carcinomaManagement of mRCCPoor-risk metastatic renal cell carcinomaInitial systemic therapyReviewThe treatment landscapeTargeted therapy eraUpfront cytoreductive nephrectomyViable treatment approachSequence of surgeryTherapy eraTreatment landscapeUnselected patientsSurgical managementSummaryRecent evidenceRecent FindingsOneTreatment approachesNephrectomyTherapyOptimal rolePatients
2019
Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
Abello A, Kenney P. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. 2019, 411-435. DOI: 10.1007/978-3-030-24378-4_24.Peer-Reviewed Original ResearchRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaDisease-free survivalHigh-risk subsetVenous tumor thrombusTyrosine kinase inhibitorsAdjuvant settingCytoreductive nephrectomyUnresectable diseaseAdjuvant therapyAdvanced diseaseNeoadjuvant therapyOverall survivalTumor thrombusGenitourinary malignanciesPartial nephrectomySignificant causeTherapyEffective agentNephrectomyMonoclonal antibodiesKinase inhibitorsDisease913 Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A retrospective cohort study
Tan W, Trinh Q, Hayn M, Marchese M, Lipsitz S, Nabi J, Kilbridge K, Kibel A, Sun M, Chang S, Sammon J. 913 Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A retrospective cohort study. European Urology Open Science 2019, 18: e1235-e1236. DOI: 10.1016/s1569-9056(19)30887-5.Peer-Reviewed Original Research
2017
Performing all major surgical procedures robotically will prolong wait times for surgery
Shinder BM, Farber NJ, Weiss RE, Jang TL, Kim IY, Singer EA, Elsamra SE. Performing all major surgical procedures robotically will prolong wait times for surgery. Robotic Surgery Research And Reviews 2017, 4: 87-91. PMID: 28890901, PMCID: PMC5586216, DOI: 10.2147/rsrr.s135713.Peer-Reviewed Original ResearchMajor surgical proceduresFellowship-trained surgeonsUrologic oncology proceduresHealth care systemRadical nephrectomyNumber of prostatectomiesSingle institutionTime patientsPartial nephrectomySurgery timeSurgical proceduresSurgical casesOncology proceduresNumber of casesSurgeryRobotic proceduresSurgical fieldMost hospitalsCare systemSurgeonsNumber of daysRS timeNephrectomyPatientsCalendar year
2016
Utilization trends and outcomes up to 3 months of open, laparoscopic, and robotic partial nephrectomy
Pak J, Lee J, Bilal K, Finkelstein M, Palese M. Utilization trends and outcomes up to 3 months of open, laparoscopic, and robotic partial nephrectomy. Journal Of Robotic Surgery 2016, 11: 223-229. PMID: 27804062, DOI: 10.1007/s11701-016-0650-4.Peer-Reviewed Original ResearchConceptsRobotic partial nephrectomyPartial nephrectomyInpatient complicationsRobotic approachResearch Cooperative System databaseUtilization trendsExcess hospital chargesShort-term outcomesInvasive partial nephrectomyLaparoscopic cohortHospital dischargeProlonged lengthBlood transfusionNew York StateHospital chargesReadmission riskSurgical approachAdministrative databasesInvasive approachStatewide PlanningKidney cancerHigh riskNephrectomyRobotic casesPatientsPresence and percentage of type 2 papillary RCC in mixed (type 1 and type 2) papillary renal cell carcinoma does not portend worse prognosis in patients treated by partial/radical nephrectomy in non-metastatic disease.
Leone A, Diorio G, Brito J, Zargar K, Pareek G, Renzulli J, Dickinson S, Amin A, Sexton W, Spiess P, Poch M, Golijanin D. Presence and percentage of type 2 papillary RCC in mixed (type 1 and type 2) papillary renal cell carcinoma does not portend worse prognosis in patients treated by partial/radical nephrectomy in non-metastatic disease. Journal Of Clinical Oncology 2016, 34: e16126-e16126. DOI: 10.1200/jco.2016.34.15_suppl.e16126.Peer-Reviewed Original Research
2015
Keratinized squamous metaplasia of the upper urinary tract resulting in recurrent renal colic.
Ghali F, Pattison E, Pais V. Keratinized squamous metaplasia of the upper urinary tract resulting in recurrent renal colic. Clinical Nephrology 2015, 84: 251-3. PMID: 26249552, DOI: 10.5414/cn108581.Peer-Reviewed Original ResearchConceptsUpper urinary tractRenal colicRecurrent renal colicUrinary tractSquamous metaplasiaChronic irritationSevere renal colicSquamous cell cancerConservative managementIrritative symptomsCell cancerRenal pelvisPremalignant lesionsStone diseaseKeratin debrisColicSymptomsTractRare phenomenonMetaplasiaIrritationExtensive historyNephrectomyPatientsUreterMET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
Shuch B, Falbo R, Parisi F, Adeniran A, Kluger Y, Kluger HM, Jilaveanu LB. MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors. BioMed Research International 2015, 2015: 192406. PMID: 26448928, PMCID: PMC4584049, DOI: 10.1155/2015/192406.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaCell renal cell carcinomaMetastatic sitesRenal cell carcinomaMET expressionCell carcinomaPredictive biomarkersPrimary tumorMetastatic clear cell renal cell carcinomaMetastatic kidney cancerAppropriate patient selectionDistant metastatic sitesPatient selectionMetastatic tissuesKidney cancerMET pathwayTissue microarrayBiomarker assessmentNumber of casesPrimary siteModerate concordancePathway inhibitorTumorsDistant tissuesNephrectomyMP84-05 VARIATION IN SURGICAL MARGIN STATUS BY SURGICAL APPROACH AMONG PATIENTS UNDERGOING PARTIAL NEPHRECTOMY FOR SMALL RENAL MASSES
Kiechle J, Abouassaly R, Tabayoyong W, Dong S, Smaldone M, Cherullo E, Gross C, Shah N, Zhu H, Kim S. MP84-05 VARIATION IN SURGICAL MARGIN STATUS BY SURGICAL APPROACH AMONG PATIENTS UNDERGOING PARTIAL NEPHRECTOMY FOR SMALL RENAL MASSES. Journal Of Urology 2015, 193: e1059. DOI: 10.1016/j.juro.2015.02.1972.Peer-Reviewed Original ResearchMP57-16 ANTIPLATELET/ANTICOAGULATION THERAPY DOES NOT INCREASE IMMEDIATE COMPLICATIONS IN PATIENTS UNDERGOING ROBOTIC PARTIAL NEPHRECTOMY (RPN)
Leone A, Turini G, Brito J, Tran T, Renzulli J, Pareek G, Golijanin D. MP57-16 ANTIPLATELET/ANTICOAGULATION THERAPY DOES NOT INCREASE IMMEDIATE COMPLICATIONS IN PATIENTS UNDERGOING ROBOTIC PARTIAL NEPHRECTOMY (RPN). Journal Of Urology 2015, 193: e695-e696. DOI: 10.1016/j.juro.2015.02.2004.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply